<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p179" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_179{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_179{left:306px;bottom:30px;}
#t3_179{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_179{left:346px;bottom:30px;}
#t5_179{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_179{left:517px;bottom:30px;}
#t7_179{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_179{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_179{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_179{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_179{left:35px;bottom:777px;letter-spacing:0.12px;word-spacing:0.07px;}
#tc_179{left:306px;bottom:785px;}
#td_179{left:351px;bottom:777px;letter-spacing:-0.04px;word-spacing:0.23px;}
#te_179{left:35px;bottom:754px;letter-spacing:0.01px;word-spacing:0.18px;}
#tf_179{left:35px;bottom:731px;letter-spacing:0.19px;word-spacing:-0.01px;}
#tg_179{left:35px;bottom:707px;letter-spacing:0.28px;}
#th_179{left:122px;bottom:707px;}
#ti_179{left:137px;bottom:707px;letter-spacing:0.01px;word-spacing:-0.78px;}
#tj_179{left:35px;bottom:684px;}
#tk_179{left:51px;bottom:684px;letter-spacing:0.19px;}
#tl_179{left:560px;bottom:684px;}
#tm_179{left:576px;bottom:684px;}
#tn_179{left:35px;bottom:661px;letter-spacing:0.31px;}
#to_179{left:71px;bottom:668px;letter-spacing:-0.01px;}
#tp_179{left:93px;bottom:661px;letter-spacing:-0.08px;word-spacing:-0.19px;}
#tq_179{left:35px;bottom:638px;letter-spacing:0.1px;word-spacing:0.1px;}
#tr_179{left:35px;bottom:614px;letter-spacing:0.01px;}
#ts_179{left:108px;bottom:622px;}
#tt_179{left:153px;bottom:614px;letter-spacing:-0.02px;word-spacing:0.21px;}
#tu_179{left:35px;bottom:591px;letter-spacing:0.12px;word-spacing:0.06px;}
#tv_179{left:243px;bottom:599px;letter-spacing:0.1px;}
#tw_179{left:288px;bottom:591px;letter-spacing:-0.02px;word-spacing:0.2px;}
#tx_179{left:35px;bottom:568px;letter-spacing:0.1px;word-spacing:0.08px;}
#ty_179{left:35px;bottom:545px;letter-spacing:0.03px;word-spacing:0.15px;}
#tz_179{left:35px;bottom:522px;letter-spacing:0.11px;word-spacing:-0.9px;}
#t10_179{left:35px;bottom:498px;letter-spacing:-0.04px;word-spacing:0.83px;}
#t11_179{left:204px;bottom:498px;letter-spacing:0.18px;}
#t12_179{left:284px;bottom:498px;letter-spacing:0.16px;}
#t13_179{left:35px;bottom:459px;letter-spacing:0.2px;}
#t14_179{left:35px;bottom:430px;letter-spacing:0.08px;word-spacing:-0.12px;}
#t15_179{left:35px;bottom:407px;letter-spacing:0.02px;word-spacing:-0.54px;}
#t16_179{left:35px;bottom:383px;letter-spacing:0.09px;word-spacing:0.09px;}
#t17_179{left:35px;bottom:360px;letter-spacing:0.18px;word-spacing:0.01px;}
#t18_179{left:35px;bottom:337px;letter-spacing:0.14px;word-spacing:-0.43px;}
#t19_179{left:35px;bottom:314px;letter-spacing:-0.1px;word-spacing:0.27px;}
#t1a_179{left:131px;bottom:321px;letter-spacing:-0.01px;}
#t1b_179{left:35px;bottom:275px;letter-spacing:-0.12px;word-spacing:0.54px;}
#t1c_179{left:35px;bottom:251px;letter-spacing:0.09px;word-spacing:-0.62px;}
#t1d_179{left:35px;bottom:228px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1e_179{left:35px;bottom:205px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t1f_179{left:35px;bottom:182px;letter-spacing:0.02px;word-spacing:0.17px;}
#t1g_179{left:35px;bottom:159px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1h_179{left:411px;bottom:166px;letter-spacing:-0.01px;}
#t1i_179{left:434px;bottom:159px;letter-spacing:0.15px;word-spacing:0.03px;}
#t1j_179{left:35px;bottom:135px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1k_179{left:35px;bottom:112px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1l_179{left:35px;bottom:89px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1m_179{left:35px;bottom:66px;letter-spacing:-0.01px;word-spacing:0.19px;}
#t1n_179{left:618px;bottom:777px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1o_179{left:1057px;bottom:785px;}
#t1p_179{left:1102px;bottom:777px;letter-spacing:0.28px;word-spacing:-0.1px;}
#t1q_179{left:618px;bottom:754px;letter-spacing:0.1px;word-spacing:-0.91px;}
#t1r_179{left:618px;bottom:731px;letter-spacing:0.4px;word-spacing:-0.21px;}
#t1s_179{left:753px;bottom:738px;letter-spacing:-0.01px;}
#t1t_179{left:776px;bottom:731px;letter-spacing:0.1px;word-spacing:0.08px;}
#t1u_179{left:618px;bottom:707px;letter-spacing:0.15px;word-spacing:-0.36px;}
#t1v_179{left:618px;bottom:684px;letter-spacing:0.15px;word-spacing:0.03px;}
#t1w_179{left:618px;bottom:661px;letter-spacing:0.13px;word-spacing:0.05px;}
#t1x_179{left:618px;bottom:638px;letter-spacing:-0.01px;}
#t1y_179{left:694px;bottom:645px;letter-spacing:-0.01px;}
#t1z_179{left:716px;bottom:638px;letter-spacing:0.12px;word-spacing:-1.16px;}
#t20_179{left:618px;bottom:614px;letter-spacing:0.08px;word-spacing:0.11px;}
#t21_179{left:618px;bottom:591px;letter-spacing:0.07px;word-spacing:0.12px;}
#t22_179{left:618px;bottom:568px;letter-spacing:0.15px;word-spacing:0.05px;}
#t23_179{left:1051px;bottom:568px;}
#t24_179{left:1067px;bottom:568px;letter-spacing:0.22px;word-spacing:-0.03px;}
#t25_179{left:1117px;bottom:576px;letter-spacing:-0.01px;}
#t26_179{left:618px;bottom:529px;letter-spacing:0.12px;word-spacing:0.09px;}
#t27_179{left:618px;bottom:506px;letter-spacing:0.12px;word-spacing:0.07px;}
#t28_179{left:618px;bottom:482px;letter-spacing:0.17px;word-spacing:0.02px;}
#t29_179{left:618px;bottom:459px;letter-spacing:0.03px;word-spacing:0.16px;}
#t2a_179{left:618px;bottom:436px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t2b_179{left:618px;bottom:413px;letter-spacing:0.04px;word-spacing:0.15px;}
#t2c_179{left:618px;bottom:390px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2d_179{left:618px;bottom:366px;letter-spacing:0.18px;word-spacing:-0.36px;}
#t2e_179{left:618px;bottom:343px;letter-spacing:0.09px;word-spacing:0.09px;}
#t2f_179{left:618px;bottom:320px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2g_179{left:618px;bottom:297px;letter-spacing:0.12px;word-spacing:-0.96px;}
#t2h_179{left:1133px;bottom:304px;}
#t2i_179{left:618px;bottom:273px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2j_179{left:618px;bottom:250px;letter-spacing:0.13px;word-spacing:-1.04px;}
#t2k_179{left:618px;bottom:227px;letter-spacing:0.07px;word-spacing:0.12px;}
#t2l_179{left:618px;bottom:204px;letter-spacing:0.36px;}
#t2m_179{left:649px;bottom:211px;letter-spacing:-0.01px;}
#t2n_179{left:672px;bottom:204px;letter-spacing:0.02px;word-spacing:0.17px;}
#t2o_179{left:618px;bottom:181px;letter-spacing:0.13px;word-spacing:-1.18px;}
#t2p_179{left:807px;bottom:181px;}
#t2q_179{left:821px;bottom:181px;letter-spacing:0.05px;word-spacing:-1.09px;}
#t2r_179{left:618px;bottom:157px;letter-spacing:0.1px;word-spacing:0.08px;}
#t2s_179{left:618px;bottom:134px;letter-spacing:0.12px;word-spacing:-1.17px;}
#t2t_179{left:618px;bottom:111px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2u_179{left:618px;bottom:88px;letter-spacing:0.13px;word-spacing:-0.06px;}
#t2v_179{left:618px;bottom:64px;letter-spacing:0.02px;word-spacing:0.18px;}
#t2w_179{left:941px;bottom:72px;letter-spacing:-0.01px;}
#t2x_179{left:964px;bottom:64px;letter-spacing:0.01px;word-spacing:0.18px;}
#t2y_179{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_179{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_179{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_179{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_179{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_179{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_179{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_179{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_179{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s8_179{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts179" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg179Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg179" style="-webkit-user-select: none;"><object width="1210" height="935" data="179/179.svg" type="image/svg+xml" id="pdf179" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_179" class="t s0_179">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_179" class="t s1_179">© </span>
<span id="t3_179" class="t s0_179">(NCCN </span>
<span id="t4_179" class="t s1_179">© </span>
<span id="t5_179" class="t s0_179">), All rights reserved. NCCN Guidelines </span>
<span id="t6_179" class="t s1_179">® </span>
<span id="t7_179" class="t s0_179">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_179" class="t s2_179">NCCN Guidelines Version 4.2024 </span>
<span id="t9_179" class="t s2_179">Head and Neck Cancers </span>
<span id="ta_179" class="t s3_179">MS-38 </span>
<span id="tb_179" class="t s4_179">with a significantly poorer outcome. </span>
<span id="tc_179" class="t s5_179">487-492 </span>
<span id="td_179" class="t s4_179">A meta-analysis including 13 </span>
<span id="te_179" class="t s4_179">studies showed that plasma EBV DNA levels assessed pre-treatment </span>
<span id="tf_179" class="t s4_179">were independent prognostic factors for mortality (HR, 2.81; 95% CI, </span>
<span id="tg_179" class="t s4_179">2.44–3.24; </span><span id="th_179" class="t s6_179">P </span><span id="ti_179" class="t s4_179">&lt; .001) and distant metastasis (HR, 3.89; 95% CI, 3.39–4.47; </span>
<span id="tj_179" class="t s6_179">P </span><span id="tk_179" class="t s4_179">&lt; .001), although these studies were significantly heterogeneous ( </span><span id="tl_179" class="t s6_179">P </span><span id="tm_179" class="t s4_179">= </span>
<span id="tn_179" class="t s4_179">.03). </span>
<span id="to_179" class="t s5_179">493 </span>
<span id="tp_179" class="t s4_179">Plasma EBV DNA has also been studied as an indicator of disease </span>
<span id="tq_179" class="t s4_179">response to chemotherapy or chemoradiation prior to additional </span>
<span id="tr_179" class="t s4_179">treatment </span>
<span id="ts_179" class="t s5_179">494-496 </span>
<span id="tt_179" class="t s4_179">and in patients with distant metastases and with disease </span>
<span id="tu_179" class="t s4_179">that is treatment-refractory. </span>
<span id="tv_179" class="t s5_179">497,498 </span>
<span id="tw_179" class="t s4_179">Studies have incorporated plasma EBV </span>
<span id="tx_179" class="t s4_179">DNA to assign patients to different post radiation adjuvant therapies, but </span>
<span id="ty_179" class="t s4_179">this approach has yet to be validated in clinical trial results (eg, </span>
<span id="tz_179" class="t s4_179">NCT02135042). Most of these studies have been based on real-time PCR </span>
<span id="t10_179" class="t s4_179">assays amplifying the </span><span id="t11_179" class="t s6_179">BamHI-W </span><span id="t12_179" class="t s4_179">fragment. </span>
<span id="t13_179" class="t s3_179">Treatment </span>
<span id="t14_179" class="t s4_179">Most recent clinical trial data regarding treatment of NPC are restricted to </span>
<span id="t15_179" class="t s4_179">EBV-associated disease. Prospective studies including patients with EBV- </span>
<span id="t16_179" class="t s4_179">negative disease are largely absent or are represented only as non- </span>
<span id="t17_179" class="t s4_179">prospectively defined subsets, mostly in studies conducted in the United </span>
<span id="t18_179" class="t s4_179">States prior to the routine use of EBV for eligibility and monitoring in NPC </span>
<span id="t19_179" class="t s4_179">clinical trials. </span>
<span id="t1a_179" class="t s5_179">499 </span>
<span id="t1b_179" class="t s7_179">Early-Stage and Locoregionally Advanced Disease </span>
<span id="t1c_179" class="t s4_179">The Intergroup trial 0099, which randomly assigned patients to EBRT with </span>
<span id="t1d_179" class="t s4_179">concurrent cisplatin plus adjuvant chemotherapy with cisplatin and 5- </span>
<span id="t1e_179" class="t s4_179">fluorouracil (PF) for three cycles versus EBRT alone, closed early when an </span>
<span id="t1f_179" class="t s4_179">interim analysis disclosed a highly significant survival advantage favoring </span>
<span id="t1g_179" class="t s4_179">the combined chemotherapy and radiation group. </span>
<span id="t1h_179" class="t s5_179">318 </span>
<span id="t1i_179" class="t s4_179">The addition of </span>
<span id="t1j_179" class="t s4_179">chemotherapy also decreased local, regional, and distant recurrence </span>
<span id="t1k_179" class="t s4_179">rates. This study was conducted in the United States, and subsequent </span>
<span id="t1l_179" class="t s4_179">phase III randomized trials in Asia confirmed that concurrent </span>
<span id="t1m_179" class="t s4_179">chemoradiation without adjuvant PF similarly increased survival in </span>
<span id="t1n_179" class="t s4_179">endemic-area populations when compared with RT alone. </span>
<span id="t1o_179" class="t s5_179">500-503 </span>
<span id="t1p_179" class="t s4_179">In one of </span>
<span id="t1q_179" class="t s4_179">these trials, 5-year OS was 70% for the chemoradiation group versus 59% </span>
<span id="t1r_179" class="t s4_179">for the RT group. </span>
<span id="t1s_179" class="t s5_179">500 </span>
<span id="t1t_179" class="t s4_179">A randomized study conducted in Singapore, which </span>
<span id="t1u_179" class="t s4_179">was modeled after the Intergroup 0099 treatment regimen, confirmed the </span>
<span id="t1v_179" class="t s4_179">benefit of adding concurrent platinum to RT with adjuvant PF, using a </span>
<span id="t1w_179" class="t s4_179">multiday infusion of platinum instead of a single bolus high-dose </span>
<span id="t1x_179" class="t s4_179">approach. </span>
<span id="t1y_179" class="t s5_179">502 </span>
<span id="t1z_179" class="t s4_179">One of the largest phase III randomized trials ever conducted </span>
<span id="t20_179" class="t s4_179">in NPC comparing concurrent cisplatin/RT with (or without) adjuvant PF </span>
<span id="t21_179" class="t s4_179">showed that adjuvant chemotherapy did not significantly improve survival </span>
<span id="t22_179" class="t s4_179">following chemoradiation (HR, 0.74; 95% CI, 0.49–1.10; </span><span id="t23_179" class="t s6_179">P </span><span id="t24_179" class="t s4_179">= .13). </span>
<span id="t25_179" class="t s5_179">504 </span>
<span id="t26_179" class="t s4_179">Advanced radiation techniques are recommended for curative-intent </span>
<span id="t27_179" class="t s4_179">treatment of NPC and to minimize the long-term side effects that are </span>
<span id="t28_179" class="t s4_179">common in survivors. IMRT is now preferred due to its ability to </span>
<span id="t29_179" class="t s4_179">encompass all areas of cancer spread, which can be located in close </span>
<span id="t2a_179" class="t s4_179">proximity to the brainstem, temporal lobes, cochleae, and optic nerves and </span>
<span id="t2b_179" class="t s4_179">chiasm. Randomized trials evaluating the optimal use of concurrent </span>
<span id="t2c_179" class="t s4_179">systemic therapy/RT for locoregionally advanced NPC were largely </span>
<span id="t2d_179" class="t s4_179">completed prior to the routine practice of IMRT, under earlier-era staging </span>
<span id="t2e_179" class="t s4_179">systems. Meta-analyses published in 2017 and 2018 showed that the </span>
<span id="t2f_179" class="t s4_179">addition of chemotherapy to IMRT did not improve survival outcomes in </span>
<span id="t2g_179" class="t s4_179">stage II disease (ie, T0–2, N1 and T2, N0), compared to IMRT alone. </span>
<span id="t2h_179" class="t s5_179">505-507 </span>
<span id="t2i_179" class="t s4_179">A multicenter randomized phase II trial from China also showed that the </span>
<span id="t2j_179" class="t s4_179">addition of concurrent chemotherapy to IMRT did not significantly improve </span>
<span id="t2k_179" class="t s4_179">survival outcomes or disease control in patients with stage II NPC (N = </span>
<span id="t2l_179" class="t s4_179">84). </span>
<span id="t2m_179" class="t s5_179">508 </span>
<span id="t2n_179" class="t s4_179">The combined treatment was also associated with increased </span>
<span id="t2o_179" class="t s4_179">incidence of leukopenia (</span><span id="t2p_179" class="t s6_179">P </span><span id="t2q_179" class="t s4_179">= .022). Another multicenter randomized phase </span>
<span id="t2r_179" class="t s4_179">II trial from China, which also evaluated the addition of concurrent </span>
<span id="t2s_179" class="t s4_179">chemotherapy to IMRT, showed that IMRT alone was non-inferior to IMRT </span>
<span id="t2t_179" class="t s4_179">with concurrent cisplatin in 341 patients with T3, N0 disease and no </span>
<span id="t2u_179" class="t s4_179">adverse features (all nodes &lt;3 cm, no involvement of level IV/IVb nodes, </span>
<span id="t2v_179" class="t s4_179">no ENE, and EBV DNA &lt;4000 copies/mL). </span>
<span id="t2w_179" class="t s5_179">509 </span>
<span id="t2x_179" class="t s4_179">However, as this was a </span>
<span id="t2y_179" class="t s8_179">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
